Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
OCREVUS (ocrelizumab) data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS) Long-term safety analysis of all clinical trials will reinforce the consistently favourable benefit-risk profile of OCREVUS ENSPRYNG (satralizumab) data to show efficacy and safety sustained over four years of... Read more